Business Description

Sphere is a medical device business completing the development of a range of monitoring and diagnostic products designed to provide significant improvements in patient management in a number of hospital specialities. Sphere’s products are expected to allow near real time measurement of blood gases, various electrolytes and drug levels with laboratory accuracy, at the patient’s bedside. This information can be used in a wide range of medical applications and is intended to enable faster clinical decision making and consequently to improve the management of patients.

Sphere’s two most advanced products based on its proprietary microanalyser platform technology are a disposable patient-attached arterial blood analyser for use in the ICU and OR (‘Proxima’) and a device for continuous blood monitoring in the bypass circuit in patients undergoing cardiopulmonary bypass surgery (‘CPB device’). In addition, Sphere has seen the first sale of its propofol drug measurement device (‘Pelorus 1000’) during October 2011. In each case, these products will ultimately target patients requiring close monitoring and frequent levels of blood testing.

The primary market for Sphere’s products is that of POC technology and devices for the ICU and OR. Sphere is initially focused on achieving commercial success with its two core microanalyser technology products in this substantial market, where frequent analysis and rapid provision of information may materially affect the management of patients and the costs of their treatments. Sphere has also examined in detail the potential application of the microanalyser technology in neonatal intensive care as well as carrying out a successful feasibility study with a world-leading company in the renal therapeutic area. The Directors believe that there are many further applications of Sphere’s microanalyser platform technology, which may be explored to enable the future expansion of Sphere’s product roadmap and revenue opportunities in the future.

Sphere is incorporated in England and its principal place of business and head office are at Harston Mill, Harston, Cambridge CB22 7GG, UK.

Investor Relations